Difference between revisions of "Part:BBa K3504011"
AhmedAdel01 (Talk | contribs) (→Usage) |
AhmedAdel01 (Talk | contribs) (→Usage) |
||
| Line 7: | Line 7: | ||
==Usage== | ==Usage== | ||
An adjuvant (45 amino acid long β-defensin) was bound with the aid of the EAAAK linker at the start (to the MEV N-terminal). EAAAK linker reduces connection with other protein areas with efficient detachment and increases stability [88,89]. The vaccine’s immunogenicity may increase with an adjuvant. Epitopes were merged together based on their interaction’s compatibility in a sequential manner with AAY and GPGPG linkers, respectively. AAY and GPGPG prevent the production of junctional epitopes, that is the main task in the construction of multiepitope vaccines; on the other hand, they promote the immunization and epitope presentation. | An adjuvant (45 amino acid long β-defensin) was bound with the aid of the EAAAK linker at the start (to the MEV N-terminal). EAAAK linker reduces connection with other protein areas with efficient detachment and increases stability [88,89]. The vaccine’s immunogenicity may increase with an adjuvant. Epitopes were merged together based on their interaction’s compatibility in a sequential manner with AAY and GPGPG linkers, respectively. AAY and GPGPG prevent the production of junctional epitopes, that is the main task in the construction of multiepitope vaccines; on the other hand, they promote the immunization and epitope presentation. | ||
| + | |||
| + | References : | ||
| + | |||
| + | Tahir ul Qamar, Muhammad, et al. “Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach.” Vaccines, vol. 8, no. 2, 1 June 2020, p. 288, www.mdpi.com/2076-393X/8/2/288/htm, 10.3390/vaccines8020288. Accessed 22 Oct. 2020. | ||
==Characterization== | ==Characterization== | ||
Revision as of 08:08, 22 October 2020
Multi-Epitope TNBC Vaccine Version (1)
Part Description
A multi-epitope vaccine formed of highly expressed and specific TNBC neo-epitopes and specifically chosen according to egyptian population alleles which can work as a generalized vaccine and also personalized vaccine which would illicit an immune response specific to TNBC tumor cells
Usage
An adjuvant (45 amino acid long β-defensin) was bound with the aid of the EAAAK linker at the start (to the MEV N-terminal). EAAAK linker reduces connection with other protein areas with efficient detachment and increases stability [88,89]. The vaccine’s immunogenicity may increase with an adjuvant. Epitopes were merged together based on their interaction’s compatibility in a sequential manner with AAY and GPGPG linkers, respectively. AAY and GPGPG prevent the production of junctional epitopes, that is the main task in the construction of multiepitope vaccines; on the other hand, they promote the immunization and epitope presentation.
References :
Tahir ul Qamar, Muhammad, et al. “Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach.” Vaccines, vol. 8, no. 2, 1 June 2020, p. 288, www.mdpi.com/2076-393X/8/2/288/htm, 10.3390/vaccines8020288. Accessed 22 Oct. 2020.
Characterization
Improvements
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 120
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 120
Illegal NotI site found at 44 - 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 120
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 120
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI.rc site found at 584
Illegal BsaI.rc site found at 935
Illegal SapI.rc site found at 853